Scarica l'app Stockscreener
21.79
4.93%
-1.13
Dopo l'orario di chiusura:
20.79
-1.00
-4.59%
Precedente Chiudi:
$22.92
Aprire:
$22.3
Volume 24 ore:
1.93M
Relative Volume:
2.52
Capitalizzazione di mercato:
$1.54B
Reddito:
$80.89M
Utile/perdita netta:
$-144.73M
Rapporto P/E:
-7.3367
EPS:
-2.97
Flusso di cassa netto:
$-83.87M
1 W Prestazione:
-22.57%
1M Prestazione:
-13.01%
6M Prestazione:
+31.34%
1 anno Prestazione:
+245.87%
Intervallo 1D:
$20.65
$22.71
Intervallo di 1 settimana:
$20.65
$28.20
Portata 52W:
$5.65
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Confronta NRIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| NRIX | 21.79 | 1.54B | 80.89M | -144.73M | -83.87M | -2.97 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap DownHere's Why - MarketBeat
Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail
Occidental Petroleum Corp (OXY-N) QuotePress Release - The Globe and Mail
Nurix Therapeutics Presents Preclinical Data from Two - GlobeNewswire
Nurix Reports Strong Preclinical Data for Two Novel Autoimmune Disease Treatments | NRIX Stock News - StockTitan
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.7%Should You Sell? - MarketBeat
Redmile Group, LLC Expands Stake in Nurix Therapeutics Inc - GuruFocus.com
Significant Stake Increase by Baker Bros. Advisors in Nurix Ther - GuruFocus.com
WASATCH ADVISORS LP Adjusts Stake in Nurix Therapeutics Inc - GuruFocus.com
When the Price of (NRIX) Talks, People Listen - Stock Traders Daily
Conocophillips (COP-N) QuotePress Release - The Globe and Mail
Wellington Management Group LLP Increases Stake in Nurix Therape - GuruFocus.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by International Assets Investment Management LLC - Defense World
ARK Investment Management LLC Has $49.80 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $27.61 By Investing.com - Investing.com Canada
Morgan Stanley's Strategic Reduction in Nurix Therapeutics Holdi - GuruFocus.com
Nurix Therapeutics (NASDAQ:NRIX) Hits New 1-Year HighHere's Why - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $27.61 - Investing.com India
Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25% - Simply Wall St
Cisco Systems Inc (CSCO-Q) QuotePress Release - The Globe and Mail
The Analyst Verdict: Nurix Therapeutics In The Eyes Of 10 Experts - Benzinga
Nurix Therapeutics' (NRIX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Nurix therapeutics' chief legal officer sells $82,250 in stock - Investing.com India
SEC Form 424B5 filed by Nurix Therapeutics Inc. - Quantisnow
Nurix therapeutics' chief legal officer sells $82,250 in stock By Investing.com - Investing.com UK
(NRIX) Technical Pivots with Risk Controls - Stock Traders Daily
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock - Investing.com India
Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock - MarketBeat
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock By Investing.com - Investing.com Australia
Nurix therapeutics chief legal officer sells $139,866 in stock By Investing.com - Investing.com South Africa
Nurix therapeutics chief legal officer sells $139,866 in stock - Investing.com India
Insider Sale: CFO Houte Van Sells Shares of Nurix Therapeutics I - GuruFocus.com
Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth - Simply Wall St
Nurix therapeutics chief legal officer sells shares worth over $101k - Investing.com Australia
Nurix therapeutics chief legal officer sells shares worth over $101k By Investing.com - Investing.com South Africa
Nurix therapeutics chief scientific officer sells shares worth $83,536 - Investing.com
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock - Investing.com
Nurix therapeutics CFO Hans van Houte sells $57,554 in stock By Investing.com - Investing.com Australia
Nurix therapeutics chief scientific officer sells shares worth $83,536 By Investing.com - Investing.com Australia
Allspring Global Investments Holdings LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Magna International Inc (MG-T) QuotePress Release - The Globe and Mail
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.46 By Investing.com - Investing.com Canada
Nurix Therapeutics (NASDAQ:NRIX) Now Covered by UBS Group - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Reaches New 1-Year HighShould You Buy? - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $26.46 - Investing.com India
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):